CPSF2

Across TCGA pan-cancer cohorts, CPSF2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CPSF2 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CPSF2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CPSF2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, CESC, and LUSC are the cancer types where CPSF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.933	0.432	.013	26	view →
CESC	DFS	Median	II,III,IV	0.144	0.705	.006	24	view →
LUSC	OS	Median	All	0.477	0.777	.027	9	view →
BLCA	DFS	Median	All	1.000	0.329	.033	6	view →
LIHC	OS	Median	All	0.144	0.704	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CPSF2–UCEC (DFS)

Open the UCEC breakdown →